There are no licensed treatments for non-alcoholic fatty liver disease (NAFLD), but three
different classes of antihyperglycaemic drugs—peroxisome proliferator-activated receptor …

As the worldwide prevalence of chronic liver diseases is high and continuing to increase,
there is an urgent need for treatment to prevent cirrhosis‐related morbidity and mortality …

Current therapeutic strategies for treating nonalcoholic steatohepatitis (NASH) have failed to
alleviate liver fibrosis, which is a devastating feature leading to hepatic dysfunction. Here …

BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is chronic, with its progression
leading to liver fibrosis and end-stage cirrhosis. Although NAFLD is increasingly common …

The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its
advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing …

Non‐alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health
because of high global prevalence and lack of evidence‐based therapies. Most animal …

Metabolic dysfunction-associated fatty liver disease (MAFLD), proposed in 2020 is a novel
term for non-alcoholic fatty liver disease (NAFLD) which was coined for the first time in 1980 …

Platelet-derived growth factor receptor β (PDGFRβ) plays an important role in hepatic
fibrosis and is closely associated with hepatic stellate cells (HSCs) activation. Previously, by …

Chronic liver inflammation, a pervasive global health issue, results in millions of annual
deaths due to its progression from fibrosis to the more severe forms of cirrhosis and …

The prevalence of nonalcoholic fatty liver disease (NAFLD) in the United States is 38%,
having increased by 50% within the past 3 decades. The estimated NAFLD prevalence …